venBio Partners LLC Long-Term Concentrated

CIK: 0001776382 · Show all filings

Period: Q1 2025 (← Previous) (Next →)

Filing Date: May 15, 2025

Total Value ($000): $123,556 (100.0% shares, 0.0% debt)

Holdings (7)

PHVS PHARVARIS N V 54.5%

Value ($000) $67,342 Shares 4,289,304 Est. Cost $21.15 Unrealized -20.3%

ALMS ALUMIS INC 13.9%

Value ($000) $17,115 Shares 2,787,398 Est. Cost $13.30 Unrealized -56.3%

HRMY HARMONY BIOSCIENCES HLDGS IN 13.1%

Value ($000) $16,236 Shares 489,194 Est. Cost $36.46 Unrealized -1.7%

— ACELYRIN INC 7.6%

Value ($000) $9,402 Shares 3,806,410 Est. Cost $20.90 Unrealized —

ALXO ALX ONCOLOGY HLDGS INC 4.9%

Value ($000) $6,043 Shares 9,699,925 Est. Cost $39.31 Unrealized -96.9%

— LYELL IMMUNOPHARMA INC 3.1%

Value ($000) $3,821 Shares 7,102,190 Est. Cost $0.64 Unrealized —

ARTV ARTIVA BIOTHERAPEUTICS INC 2.9%

Value ($000) $3,597 Shares 1,198,975 Est. Cost $11.59 Unrealized -53.4%

Ticker	Issuer	Shares	Value ($000)	%	Est. Cost	Unrealized	Class	CUSIP
PHVS	PHARVARIS N V	4,289,304	$67,342	54.5%	$21.15	-20.3%	COM	N69605108
ALMS	ALUMIS INC	2,787,398	$17,115	13.9%	$13.30	-56.3%	COM	022307102
HRMY	HARMONY BIOSCIENCES HLDGS IN	489,194	$16,236	13.1%	$36.46	-1.7%	COM	413197104
—	ACELYRIN INC	3,806,410	$9,402	7.6%	$20.90	—	COM	00445A100
ALXO	ALX ONCOLOGY HLDGS INC	9,699,925	$6,043	4.9%	$39.31	-96.9%	COM	00166B105
—	LYELL IMMUNOPHARMA INC	7,102,190	$3,821	3.1%	$0.64	—	COM	55083R104
ARTV	ARTIVA BIOTHERAPEUTICS INC	1,198,975	$3,597	2.9%	$11.59	-53.4%	COM	04317A107